AZD2693 is a PNPLA3 inhibitor. This study is intended to investigate the safety and tolerability, pharmacokinetics, and pharmacodynamics of AZD2693 in NASH patients carrying PNPLA3-rs738409. Here, PNPLA3 is linked to metabolic dysfunction-associated steatohepatitis.